Abstract: A polysilicone base for medical and cosmetic compositions includes a dimethicone fluid, a volatile cyclosiloxane, a silicone elastomer, and nanoparticulate silica. The polysilicone base may also include one or more therapeutic agents for reducing the formation and appearance of scar tissue at the site of a wound. The polysilicone base is spreadable, but does not run off of the wound site. The polysilicone base is phase-stable, in that it does not separate into phases.

Abstract: A skin care method and kit is disclosed that includes instructions for a dietary skin care regimen. The regimen includes a list of prohibited and allowed foods. The list of prohibited foods includes red meat, chocolate, eggs, confections, alcoholic beverages, shellfish, fried foods, and tomatoes. The list of allowed foods includes chicken, turkey, non-fried fish, vegetables, fruit other than a tomato, and olive oil as a salad dressing. The skin care kit further includes a compliance report including the list of prohibited and allowed foods with corresponding data input fields for each food in the list of prohibited and allowed foods. The user indicates an amount of each prohibited and allowed food item consumed by the user in the corresponding data input field. A compliance rating system is disclosed in which the total number of servings of prohibited and allowed foods consumed by the user determines the user's compliance level.

Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Abstract: This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.

Abstract: The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides immunogenic compositions and methods of using the same to induce immune responses (e.g., immunity (e.g., protective immunity)) against Hepatitis B virus (HBV)). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.

Abstract: A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.

Abstract: This invention provides a dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 ?g; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose. A method of treating a patient includes administering to a patient a dry powder medicament having fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 ?g; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose.

Abstract: Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.

Abstract: The present invention provides for safe and reliable electronic circuitry that can be employed in ingestible compositions. The ingestible circuitry of the invention includes a solid support; a conductive element; and an electronic component. Each of the support, conductive element and electronic component are fabricated from an ingestible material. The ingestible circuitry finds use in a variety of different applications, including as components of ingestible identifiers, such as may be found in ingestible event markers, e.g., pharma-informatics enabled pharmaceutical compositions.

Abstract: Provided is a method for treatment of liver cancer and inhibition of metastasis with CXCR4-targeted nanoparticle. A CXCR4 antagonist is used as a targeting molecule to modify a lipid carrier for the formation of nanoparticle carrying an anti-angiogenesis drug or an anti-angiogenic nucleotide. Such nanoparticle can enhance the accumulation and uptake of the drug and nucleotide in liver cancer cells as well as sensitize the liver cancer cells to treatment of said drug and nucleotide, providing a synergistic suppression of angiogenesis and tumor progression. Furthermore, the CXCR4-targeted nanoparticle can effectively inhibit metastasis of liver cancer. The pharmaceutical composition is an injectable composition; hence, is suitable for clinical application for the treatment of liver cancer.

Abstract: The present invention relates to a sustained-release drug composition consisting essentially of microparticles of a peptide as the active substance and a biocompatible water-soluble polymer, in particular peptide as meianocortin receptor ligand. The present invention relates also to an injection formulation comprising the sustained-release drug composition suspended in an injection medium.

Abstract: Disclosed herein are pharmaceutical compositions comprising a plurality of first beads each comprising: a core; a first layer comprising pilocarpine or a pharmaceutically acceptable salt thereof; and a second layer comprising a first polymer. Also disclosed are pharmaceutical compositions comprising a plurality of second beads each comprising: a core; and a first layer comprising tolterodine or a pharmaceutically acceptable salt thereof. Further disclosed are pharmaceutical formulations comprising: a) a plurality of the first beads; b) a plurality of the second beads; or c) a plurality of the first beads and a plurality of the second beads.

Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.

Abstract: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.

Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

Abstract: The invention relates to the use of bacterial ghosts (BG) to promote an innate immune response.

Abstract: The present invention relates to methods for improving muscle strength and treating muscular dystrophy.

Abstract: The invention relates to a system for administering active ingredients, including nanocapsules comprising an oil, a cationic surfactant and a polymer selected from the group consisting of polyglutamic acid (PGA), polyglutamic-polyethyleneglycol acid (PGA-PEG), hyaluronic acid (HA) and polyasparagine (PAsn) or a combination of same and, optionally, an active ingredient, with the condition that when the polymer includes polyglutamic acid or polyglutamic-polyethyleneglycol acid (PGA-PEG) the active ingredient is not a didemnin or a tamandarin. The invention also relates to methods for obtaining said nanocapsule system, the pharmaceutical compositions thereof and the use of same in medicine.

Abstract: Hypotonic formulations were evaluated for delivering water-soluble drugs and for drug delivery with muco-inert (that is, non-adhesive) mucus-penetrating nanoparticles (MPP). Hypotonic formulations markedly increased the rate at which drugs and MPP reached the epithelial surface, including deep into the vaginal folds. Minimally hypotonic formulations, preferably ranging from 20-220 mOsm/kg, provided rapid and uniform delivery of MPP to the entire vaginal surface, with minimal risk of epithelial toxicity. Data also show that there is a higher osmolality in the colon, such that vehicles with an osmolality above that of blood plasma (generally considered isotonic at ˜300 mOsm/kg), still lead to improvements in distribution in the colon due to rapid, osmotically-induced fluid absorption. The range for improved colon distribution with a hypotonic vehicle in the colon is ˜20 mOsm/kg-450 mOsm/kg.

Abstract: An artificial oxygen carrier (AOC) for use as a blood substitute in the body. A first gas permeable shell encloses an oxygen carrying agent. The first gas-permeable shell has a second oxygen carrying agent surrounding it, and there is a second gas-permeable shell enclosing the second agent. The concentric shells are not subject to turbulent breakup, or chemical decomposition, and do not release the oxygen carrying agents into the blood.

Abstract: According to an aspect of the invention, injectable bulking compositions are provided which contain the following: (a) fibers that are configured to prevent migration to locations in the body remote from the injection site, for example, because they have a minimum length that is sufficiently large to prevent migration of the fibers and/or because they have surface features that stimulate host tissue response to lock the fibers in position and (b) a carrier in an amount effective to render the composition injectable.

Abstract: Compositions comprising terpene compounds for the treatment of negative sensory phenomena (NSP). Negative sensory phenomena is characterized by a decreased ability to sense light touch, pin prick, vibration, temperature, pain and/or reduced proprioception. The terpene compounds are preferably aromatic terpene compounds such as geraniol and citronellol and analogs thereof. The terpenes may also be used in combination. The terpenes are derived form plant essential oils or are manufactured synthetically.

Abstract: Disclosed are compounds of formula I wherein R1, R2, R5 and R6 are as defined in the claims; such compounds have interesting pharmacological properties.

Abstract: Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.

Abstract: Disclosed herein are methods of inactivating and/or decolonizing bacteria on a surface. The present invention also discloses methods for treatment of epithelial conditions caused or aggravated by bacteria, such as acne vulgaris, in a subject in need thereof. The present invention additionally discloses inventive compounds and compositions that exhibit anti-bacterial and/or anti-inflammatory effects.

Abstract: The invention provides well-defined compounds that are either EP2 agonists, EP4 agonists, or mixed EP2/EP4 agonist. The compounds are useful for treating a variety of pathological conditions associated with activity of the EP2 and/or EP4 receptors.

Abstract: A compound which inhibits the importation of chloride into neurons and a compound which improve the outflow of chloride from neurons for the use in treatment of autism, a pharmaceutical composition for use in the treatment of autism including such compound and a pharmaceutically acceptable carrier are described.

Abstract: The field involves compositions useful for pain relief, including diclofenac solution and gel formulations, in particular methods of use thereof, articles of manufacture and kits that provide novel preclinical, clinical and other information to users.

Abstract: The present invention provides for a method of treating OCD or an Obsessive-Compulsive Spectrum Disorder (OCSD), such as BDD or ADHD, using a high-dose glycine treatment.

Abstract: The present invention relates to pharmaceutical compositions comprising D-serine transporter inhibitors and therapeutic methods using such pharmaceutical compositions in methods for the treatment of visual system disorders and the enhancement of the visual function.

Abstract: Provided herein are pharmaceutical compositions useful in the prevention and treatment of protozoan infections in mammals comprising administering to the subject a pharmaceutical composition comprising at least one membrane activated chelator compound which is a lipophilic diester derivative of the chelating agent 1,2-bis(2 aminophenoxy)ethane-N,N,N?,N?-tetraacetic acid, or a salt, solvate, stereoisomer, or prodrug thereof, as well as compositions which include at least one or more other anti-parasitic compound, and a pharmaceutically acceptable carrier, in an effective amount. Methods for prevention, treatment, and combination therapies are also provided.

Abstract: The present invention relates to short chain fatty acids (SCFA) for use in transmucosal administration to a subject for the prevention, attenuation or treatment of a disease or disorder associated with a compromised Th1 immune response and/or an unwanted Th2 or Th2-like immune response by modulating a Th2 immune response towards a Th1 immune response, particularly for the treatment, prevention and/or amelioration of viral infections and as an adjuvant for promoting the efficiency of vaccines and/or prevention of allergic diseases or disorders.

Abstract: A UGT2B inhibitor capable of increasing the bio-availability of a drug, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: capillarisin, isorhamnetin, ?-naphthoflavone, ?-naphthoflavone, hesperetin, terpineol, (+)-limonene, ?-myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, gallic acid, genistein, glycyrrhizin, protocatechuic acid, ethyl myristate, umbelliferone, PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20, Tween 60, Tween 80, BRIJ® 58, BRIJ® 76, Pluronic® F68, Pluronic® F127, and a combination thereof.

Abstract: The invention provides compositions containing omega-3 oil and at least one anti-inflammatory agent and/or at least one gastrotoxic, nephrotoxic, or hepatotoxic pharmaceutical agent. The invention further provides kits containing these compositions and methods for decreasing pain or inflammation, decreasing the symptoms of an allergic condition, and/or the gastrotoxicity, nephrotoxicity, and hepatotoxicity of a pharmaceutical agent in a subject (e.g., a human) or companion animal requiring the administration of at least one composition containing omega-3 oil. The invention also provides methods for formulating an anti-inflammatory agent to increase its absorption rate requiring the mixing of omega-3 oil with the anti-inflammatory agent and methods of concentrating an omega-3 oil.

Abstract: A pharmaceutical composition for the acute and/or chronic treatment or prevention of osteoarticular diseases includes an adequate pharmaceutical carrier or diluent, a polysaccharide and/or a glycosaminoglycan, an anti-inflammatory agent and stem cells.

Abstract: [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g.

Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.

Abstract: Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds corresponding to general formula (I) are disclosed. Also disclosed, are pharmaceutical compositions including these compounds and methods of using these compounds and compositions for the treatment of chemokine-mediated diseases.

Abstract: Methods are provided for identifying molecules that can be used to positively and negatively manipulate quorum-sensing-mediated communication to control bacterial behavior. Small-molecule antagonists that disrupt quorum-sensing-mediated activities are identified. Methods are provided for disrupting detection of acyl-homoserine lactone autoinducer in Gram-negative bacteria by contacting the bacteria with the antagonists. Methods of inhibiting quorum sensing-mediated activity in Gram-negative bacteria are provided wherein the activity is pathogenicity, bioluminescence, siderophore production, type III secretion, or metalloprotease production.

Abstract: The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: An improved process for the N-alkylation of tertiary morphinan alkaloid bases to form the corresponding quaternary morphinan alkaloid derivatives.

Abstract: The invention relates to a compound of Formula I, II, III, IV or a pharmaceutically acceptable ester or prodrug thereof:

Abstract: The present invention relates, inter alia, to methods and compositions for regulating the host response to biomaterials, including inhibiting inflammation from and rejection of biomaterials using salicylate compounds and/or TLR7/TLR9 antagonists as described herein.

Abstract: This invention relates to the use of a compound in formula (I) and its salts acceptable pharmaceutically in preparation of vasodilative drugs: Wherein, R1, R2, X, Y, A and B are defined in the invention.

Abstract: Methods and compositions for reducing frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents.

Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Abstract: Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.

Abstract: According to the invention there is provided a method for the treatment of airway hyperresponsiveness, which method comprises the administration of pemirolast, or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment. Suitable lower doses of pemirolast are least about 110 mg per day.

Abstract: The present invention relates to a process for the preparation of a solid, orally administrable pharmaceutical composition, comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide in hydrophilized form, and its use for the prophylaxis and/or treatment of diseases.